ATE427488T1 - Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion - Google Patents

Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion

Info

Publication number
ATE427488T1
ATE427488T1 AT96921473T AT96921473T ATE427488T1 AT E427488 T1 ATE427488 T1 AT E427488T1 AT 96921473 T AT96921473 T AT 96921473T AT 96921473 T AT96921473 T AT 96921473T AT E427488 T1 ATE427488 T1 AT E427488T1
Authority
AT
Austria
Prior art keywords
cell
hiv
fusion
tropic
isolate
Prior art date
Application number
AT96921473T
Other languages
English (en)
Inventor
Graham Allaway
Virginia Litwin
Paul Maddon
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE427488T1 publication Critical patent/ATE427488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96921473T 1995-06-07 1996-06-07 Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion ATE427488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47551595A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE427488T1 true ATE427488T1 (de) 2009-04-15

Family

ID=23887897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921473T ATE427488T1 (de) 1995-06-07 1996-06-07 Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion

Country Status (8)

Country Link
US (6) US6261763B1 (de)
EP (1) EP0847452B1 (de)
AT (1) ATE427488T1 (de)
AU (1) AU723158B2 (de)
CA (1) CA2224003C (de)
DE (1) DE69637890D1 (de)
ES (1) ES2325042T3 (de)
WO (1) WO1996041020A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041020A1 (en) * 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
JP4183754B2 (ja) * 1996-06-14 2008-11-19 プロジェニクス・ファーマスーティカルス・インコーポレーテッド Ｈｉｖ―１感染を阻害するためのケモカイン受容体の使用
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
CA2342675A1 (en) 2001-04-02 2002-10-02 Abdelkrim Habi Halogenated rhodamine derivatives and applications thereof
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
US20070026441A1 (en) 2005-07-22 2007-02-01 Olson William C Methods for reducing viral load in HIV-1-infected patients
US20110135634A1 (en) * 2007-07-19 2011-06-09 Olson William C Methods of inhibiting infection by diverse subtypes of drug-resistant hiv-1
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US10085783B2 (en) 2013-03-14 2018-10-02 Izi Medical Products, Llc Devices and methods for treating bone tissue
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
SG10201913958QA (en) 2015-07-15 2020-03-30 Agency Science Tech & Res Modulation of hepatitis b virus replication

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI71011C (fi) 1982-02-26 1986-10-27 Ikaplast Automatiskt handeldvapen
FI71010C (fi) 1982-02-26 1986-10-27 Ikaplast Faestanordning foer faestande av en pipa i ett vapens ram
US4886743A (en) 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5126433A (en) 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5854400A (en) 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US5668149A (en) 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
US5449608A (en) 1993-03-22 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Parvovirus B19 receptor and parvovirus B19 detection
US5603933A (en) 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
EP0738330A4 (de) * 1993-12-17 2002-10-30 Progenics Pharm Inc Verfahren zur verwendung des auf resonanzenergietransfer basierenden tests auf die durch hiv-i-hüllglycoprotein vermittelte membranfusion,und testsatz für ihre anwendung
US5504003A (en) 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US20040151719A1 (en) 1995-06-06 2004-08-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO1996039437A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human g-protein chemokine receptor hdgnr10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
MX9709849A (es) 1995-06-06 1998-03-29 Human Genome Sciences Inc Receptor de quimiocina de la proteina g humana o hdgnr10.
EP1145721A3 (de) 1995-06-06 2003-12-03 Human Genome Sciences, Inc. Menschlicher G-protein chemokinrezeptor DHDGNR10 (CCR5 Rezeptor). Pharmazeutische Zusammenstellung
WO1996041020A1 (en) 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
AU1750497A (en) 1996-01-17 1997-08-11 Progenics Pharmaceuticals, Inc. Compounds capable of inhibiting hiv-1 infection
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
EP0883687B1 (de) 1996-03-01 2004-10-27 Euroscreen S.A. Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
US6344545B1 (en) 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6107019A (en) 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US5939320A (en) 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
US20040086528A1 (en) 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
JP4183754B2 (ja) 1996-06-14 2008-11-19 プロジェニクス・ファーマスーティカルス・インコーポレーテッド Ｈｉｖ―１感染を阻害するためのケモカイン受容体の使用
US5994515A (en) 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
AU3505397A (en) 1996-06-25 1998-01-14 Trustees Of The University Of Pennsylvania, The Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6100087A (en) 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
MXPA01006097A (es) 1998-12-16 2002-04-15 Progenics Pharm Inc Inhibicion sinergistica de la fusion y union de vih-1, composiciones y anticuerpos en la misma.
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6488375B2 (en) * 1999-10-28 2002-12-03 Ocular Sciences, Inc. Tinted contact lens and method for making same
US6692745B2 (en) 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
CA2399593A1 (en) 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
AU2001247254A1 (en) 2000-02-29 2001-09-12 Aaron Diamond Aids Research Centre Sulfated CCR5 peptides for HIV -1 infection
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030092632A1 (en) 2001-02-28 2003-05-15 Tatjana Dragic Sulfated CCR5 peptides for HIV-1 infection
US20030003440A1 (en) 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
WO2002085365A1 (en) 2001-04-19 2002-10-31 Bristol-Myers Squibb Company Tricyclic compounds useful as hiv reverse transcriptase inhibitors
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CN1805740A (zh) 2003-05-16 2006-07-19 马里兰大学生物技术研究所 下调ccr5表达的组合物及其应用方法
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
US20070026441A1 (en) 2005-07-22 2007-02-01 Olson William C Methods for reducing viral load in HIV-1-infected patients

Also Published As

Publication number Publication date
WO1996041020A1 (en) 1996-12-19
US6261763B1 (en) 2001-07-17
US7862994B2 (en) 2011-01-04
US20090155774A1 (en) 2009-06-18
EP0847452A1 (de) 1998-06-17
DE69637890D1 (de) 2009-05-14
CA2224003A1 (en) 1996-12-19
US6972126B2 (en) 2005-12-06
US20020045161A1 (en) 2002-04-18
EP0847452A4 (de) 2000-04-12
US7901685B2 (en) 2011-03-08
ES2325042T3 (es) 2009-08-24
AU6269096A (en) 1996-12-30
CA2224003C (en) 2010-04-13
US20070048820A1 (en) 2007-03-01
EP0847452B1 (de) 2009-04-01
US20030044770A1 (en) 2003-03-06
US20060140977A1 (en) 2006-06-29
AU723158B2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
ATE427488T1 (de) Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
EP0724651A4 (de) Synthetische humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
PT724456E (pt) Anticorpos contra cd4
DE3070803D1 (en) Monoclonal-antibody-producing hybrid cell line, antibody and method of preparing it, therapeutic composition containing it and its diagnostic and therapeutic uses
ATE335072T1 (de) Methoden für inhibition der cd14-abhängigen zellaktivierung
PT813525E (pt) Derivados de benzamidina e sua utilizacao como anticoagulantes
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
ATE226641T1 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
GB9319877D0 (en) Novel hybridoma & monoclonal antibodies produced thereby
ES2195033T3 (es) Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
EA200001134A1 (ru) Вакцина
ES2189802T3 (es) Anticuerpos monoclonales contra ck-mb.
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
NO981051L (no) Peptidderivater
ATE132502T1 (de) Peptide, die epitope auf r-ifn-beta repräsentieren, antikörper dagegen, und ihre anwendung
DK0539450T3 (da) Fremgangsmåde til fremstilling af sulfinyl-pristinamycin IIB.
ES2051870T3 (es) Anticuerpo monoclonal capaz de suprimir la proliferacion de linfocitos t.
IT8421612A0 (it) Vettore clonante, procedimento per la sua costruzione e procedimentodi concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante.
FR2663748B1 (fr) Anticorps specifiques de la liaison isopeptidique induite par les transglutaminases, antigenes constitues par des isopeptides glu-lys reconnus par lesdits anticorps, agents de diagnostic et compositions therapeutiques les contenant.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties